In the wake of the increase in Current Liabilities in the first quarter 2025, Quick Ratio fell to 1.98 a new company low.

Within Major Pharmaceutical Preparations industry 327 other companies have achieved higher Quick Ratio than Inozyme Pharma Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 588 to 1433.

Explain Quick Ratio?
How much Cash & cash equivalents INZY�s has?
What are INZY�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

INZY Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	244.84 %	130.82 %	49.44 %	28.64 %	-1.39 %
Y / Y Cash & cash equivalent Change	-48.98 %	-40.04 %	-31.61 %	3.05 %	26.9 %
Quick Ratio MRQ	1.98	3.34	7.17	9.3	13.39
INZY's Total Ranking	# 1433	# 588	# 400	# 316	# 236
Seq. Current Liabilities Change	26.21 %	84.79 %	18.04 %	25.27 %	-15.52 %
Seq. Cash & cash equivalent Change	-25.03 %	-14.07 %	-8.94 %	-13.02 %	-11.9 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 328
Healthcare Sector	# 573
Overall Market	# 1433

Quick Ratio Statistics
High	Average	Low
21.24	11.77	1.98
(Mar 31 2021)		(Mar 31 2025)

Financial Statements
Inozyme Pharma Inc 's Current Liabilities	$ 43 Millions	Visit INZY's Balance sheet
Inozyme Pharma Inc 's Cash & cash equivalent	$ 85 Millions	Visit INZY's Balance sheet
Source of INZY's Sales		Visit INZY's Sales by Geography

Cumulative Inozyme Pharma Inc 's Quick Ratio

INZY's Quick Ratio for the trailling 12 Months

INZY Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	114.9 %	55.34 %	18.05 %	4.57 %	0.87 %
Y / Y Cash & cash equivalent TTM Growth	-31.05 %	-14.85 %	6.66 %	27.98 %	24.6 %
Quick Ratio TTM	4.29	6.93	10.35	12.6	13.36
Total Ranking TTM	# 3754	# 2368	# 2852	# 2722	# 2729
Seq. Current Liabilities TTM Growth	37.88 %	31.51 %	11.05 %	6.73 %	-0.34 %
Seq. Cash & cash equivalent TTM Growth	-14.65 %	-11.97 %	-8.79 %	0.62 %	5.4 %

Quick ratio ranking by company, industry and sector >> Back to INZY Financial Strength Comparisons >> Go to Compare INZY Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q1 2025 to $42.78 millions, cumulative Quick Ratio decreased to 4.29 below the Inozyme Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 478 other companies have achieved higher Quick Ratio than Inozyme Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 2368 to 3754.

Explain Quick Ratio?
How much Cash & cash equivalents INZY�s has?
What are INZY�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 479
Healthcare Sector	# 965
Within the Market	# 3754

trailing twelve months Quick Ratio Statistics
High	Average	Low
17.56	11.77	4.29
(Jun 30 2021)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Nucana Plc	5.43	$ 34.978 Millions	$ 6.445 Millions
Ovid Therapeutics Inc	5.41	$ 42.996 Millions	$ 7.947 Millions
Igm Biosciences Inc	5.39	$ 152.112 Millions	$ 28.198 Millions
Gossamer Bio Inc	5.35	$ 257.934 Millions	$ 48.223 Millions
Immutep Limited	5.28	$ 44.307 Millions	$ 8.386 Millions
Longeveron Inc	5.26	$ 14.327 Millions	$ 2.724 Millions
Alx Oncology Holdings Inc	5.22	$ 97.831 Millions	$ 18.742 Millions
Bio Green Med Solution Inc	5.20	$ 3.450 Millions	$ 0.663 Millions
Catalyst Pharmaceuticals Inc	5.20	$ 580.656 Millions	$ 111.649 Millions
Arcus Biosciences Inc	5.19	$ 997.000 Millions	$ 192.000 Millions
Relmada Therapeutics Inc	5.17	$ 27.061 Millions	$ 5.231 Millions
Vireo Growth Inc.	5.15	$ 86.261 Millions	$ 16.738 Millions
Forte Biosciences Inc	5.08	$ 45.856 Millions	$ 9.032 Millions
Madrigal Pharmaceuticals Inc	5.07	$ 843.068 Millions	$ 166.221 Millions
Prelude Therapeutics Inc	5.01	$ 99.074 Millions	$ 19.787 Millions
Cogent Biosciences Inc	4.98	$ 245.661 Millions	$ 49.318 Millions
Aldeyra Therapeutics Inc	4.94	$ 39.707 Millions	$ 8.031 Millions
Hepion Pharmaceuticals Inc	4.90	$ 4.586 Millions	$ 0.936 Millions
Silo Pharma Inc	4.90	$ 5.451 Millions	$ 1.113 Millions
Aclaris Therapeutics Inc	4.90	$ 105.314 Millions	$ 21.514 Millions
Pepgen Inc	4.79	$ 97.781 Millions	$ 20.431 Millions
Genelux Corporation	4.77	$ 35.102 Millions	$ 7.352 Millions
Corvus Pharmaceuticals Inc	4.76	$ 44.212 Millions	$ 9.279 Millions
Scynexis Inc	4.76	$ 40.607 Millions	$ 8.532 Millions
Cns Pharmaceuticals Inc	4.69	$ 13.048 Millions	$ 2.779 Millions
Abeona Therapeutics Inc	4.68	$ 84.155 Millions	$ 17.983 Millions
Transcode Therapeutics Inc	4.65	$ 11.681 Millions	$ 2.510 Millions
Mural Oncology Plc	4.65	$ 107.682 Millions	$ 23.153 Millions
United Therapeutics Corporation	4.60	$ 3,321.300 Millions	$ 721.500 Millions
Lantern Pharma Inc	4.60	$ 19.722 Millions	$ 4.286 Millions

Date modified: 2026-08-29T17:41:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.